Intrinsiqq
Tenaya Therapeutics, Inc. logo

Tenaya Therapeutics, Inc. Insider Trading

TNYA

Compare
Last 12 months

Insiders sold 45K and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. The last open-market buy by an executive or director was in Mar 2025.

Net open-market
−45K
0 buys · 10 sales
Under a 10b5-1 plan
0%
of the value sold
Insiders who bought / sold
0 / 3
executives and directors
Last open-market buy
Mar 2025
Mar 5, 2025

Get an email when TNYA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Nov 17No plan
    Faraz Ali
    Chief Executive Officer · sold 3,499 at $0.32
    1K
    0.6% of stake
  • Nov 17No plan
    Whittemore Tingley
    Chief Medical Officer · sold 3,223 at $0.32
    1K
    1.2% of stake
  • Aug 17No plan
    Faraz Ali
    Chief Executive Officer · sold 22,232 at avg $0.71
    16K
    5.1% of stake
  • Aug 17No plan
    Whittemore Tingley
    Chief Medical Officer · sold 7,424 at avg $0.71
    5K
    3.4% of stake
  • May 18No plan
    Faraz Ali
    Chief Executive Officer · sold 3,390 at $0.79
    3K
    0.8% of stake
  • May 18No plan
    Whittemore Tingley
    Chief Medical Officer · sold 3,121 at $0.79
    2K
    1.4% of stake
  • May 18No plan
    Tomohiro Higa
    SVP, Finance · sold 1,485 at $0.79
    1K
    1.2% of stake
  • Feb 24 – 25No plan
    TCG Opportunity III GP, LLC
    Large holder · sold 4,170,266 at avg $0.57
    $2.37M
    100% of stake
  • Feb 20 – 23No plan
    Column Group Iii-A, LP
    Large holder · sold 829,734 at avg $0.61
    503K
    27% of stake
  • Feb 17No plan
    Tomohiro Higa
    SVP, Finance · sold 3,469 at avg $0.64
    2K
    2.8% of stake
  • Feb 17No plan
    Faraz Ali
    Chief Executive Officer · sold 14,862 at avg $0.64
    10K
    3.2% of stake
  • Feb 17No plan
    Whittemore Tingley
    Chief Medical Officer · sold 5,160 at avg $0.64
    3K
    2.3% of stake
  • Feb 10 – 11No plan
    Column Group Iii-A, LP
    Large holder · sold 4,400,290 at avg $0.69
    $3.04M
    62% of stake
  • Nov 17, 2025No plan
    Tomohiro Higa
    SVP, Finance · sold 1,367 at $1.33
    2K
    1.4% of stake
  • Nov 17, 2025No plan
    Whittemore Tingley
    Chief Medical Officer · sold 2,877 at $1.33
    4K
    1.7% of stake
  • Nov 17, 2025No plan
    Faraz Ali
    Chief Executive Officer · sold 3,126 at $1.33
    4K
    1.0% of stake
  • Aug 18, 2025No plan
    Whittemore Tingley
    Chief Medical Officer · sold 5,053 at avg $1.25
    6K
    2.8% of stake
  • Aug 18, 2025No plan
    Faraz Ali
    Chief Executive Officer · sold 14,533 at avg $1.25
    18K
    4.6% of stake
  • Aug 18, 2025No plan
    Tomohiro Higa
    SVP, Finance · sold 2,962 at avg $1.25
    4K
    3.0% of stake
  • May 16, 2025No plan
    Tomohiro Higa
    SVP, Finance · sold 1,390 at $0.44
    $612
    1.4% of stake
  • May 16, 2025No plan
    Whittemore Tingley
    Chief Medical Officer · sold 2,937 at $0.44
    1K
    1.7% of stake
  • May 16, 2025No plan
    Faraz Ali
    Chief Executive Officer · sold 3,189 at $0.44
    1K
    1.0% of stake
  • Mar 10, 2025No plan
    Tomohiro Higa
    SVP, Finance · sold 2,482 at avg $0.54
    1K
    2.4% of stake
  • Mar 10, 2025No plan
    Whittemore Tingley
    Chief Medical Officer · sold 7,398 at avg $0.54
    4K
    4.1% of stake
  • Mar 10, 2025No plan
    Faraz Ali
    Chief Executive Officer · sold 9,741 at avg $0.54
    5K
    2.9% of stake
  • Mar 5, 2025
    Column Group Iii, LP
    Large holder · bought 35,714,284 at $0.70
    $25M
    263% of stake
  • Mar 5, 2025
    David V Goeddel
    Director · bought 35,714,284 at $0.70
    $25M
    263% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch TNYA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with TNYA

CompareIntrinsic value
SLDBSolid Biosciences Inc.
$6.25-2.95%10
ADMAAdma Biologics Inc.
$13.17-1.27%82
RLAYRelay Therapeutics Inc.
$16.12+1.32%40
RVMDRevolution Medicines Inc.
$161.20+1.11%10
OCGNOcugen Inc.
$0.77+4.77%40
XFORX4 Pharmaceuticals Inc.
$3.00+1.35%20
AMGNAmgen Inc.
$435.64-0.72%55
VIRVir Biotechnology Inc.
$8.39-5.41%10

Held by ETFs

TNYA is in 3 US ETFs. The largest of them, with TNYA's weight in each:

Spot a number that looks wrong? Check it in TNYA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing TNYA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.